APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs of Abuse Analysis Controls

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs of Abuse Analysis Controls Market Outlook and Growth Opportunities 2026

4 July 2026207 pages

Choose your research edition.

Industry ResearchDrugs of Abuse Analysis Controls Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs of Abuse Analysis Controls Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Drugs of Abuse Analysis Controls Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs of Abuse Analysis Controls Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs of Abuse Analysis Controls Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Drugs of Abuse Analysis Controls market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs of Abuse Analysis Controls is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs of Abuse Analysis Controls is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs of Abuse Analysis Controls is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs of Abuse Analysis Controls market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs of Abuse Analysis Controls market include American Bio Medica Corp, Bio-Rad Laboratories, BTNX, Carolina Liquid Chemistries, Cerilliant, Clarity Diagnostics LLC, Diatron, JAS Diagnostics and Kova International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs of Abuse Analysis Controls market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs of Abuse Analysis Controls and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs of Abuse Analysis Controls sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs of Abuse Analysis Controls market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs of Abuse Analysis Controls Segment by Company

American Bio Medica Corp

Bio-Rad Laboratories

BTNX

Carolina Liquid Chemistries

Cerilliant

Clarity Diagnostics LLC

Diatron

JAS Diagnostics

Kova International

Lin-Zhi International Inc

MedTest DX

Microgenics

Ortho Clinical Diagnostics

Quasar Instruments

QuidelOrtho Corporation

Beckman Coulter

Horiba

Thermo Fisher Scientific

Siemens

Abbott

Drugs of Abuse Analysis Controls Segment by Type

Liquid

Lyophilized

Others

Drugs of Abuse Analysis Controls Segment by Application

Clinical

Diagnostic Laboratories

Hospital

Others

Drugs of Abuse Analysis Controls Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs of Abuse Analysis Controls status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs of Abuse Analysis Controls market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs of Abuse Analysis Controls significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs of Abuse Analysis Controls competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs of Abuse Analysis Controls market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs of Abuse Analysis Controls and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs of Abuse Analysis Controls.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs of Abuse Analysis Controls market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs of Abuse Analysis Controls industry.

Chapter 3: Detailed analysis of Drugs of Abuse Analysis Controls manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs of Abuse Analysis Controls in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs of Abuse Analysis Controls in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs of Abuse Analysis Controls Industry Trends Table 2. Drugs of Abuse Analysis Controls Industry Drivers Table 3. Drugs of Abuse Analysis Controls Industry Opportunities and Challenges Table 4. Drugs of Abuse Analysis Controls Industry Restraints Table 5. Global Drugs of Abuse Analysis Controls Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs of Abuse Analysis Controls Revenue Share by Company (2021-2026) Table 7. Global Drugs of Abuse Analysis Controls Sales Volume by Company (k units) & (2021-2026) Table 8. Global Drugs of Abuse Analysis Controls Sales Volume Share by Company (2021-2026) Table 9. Global Drugs of Abuse Analysis Controls Average Price (USD/unit) of Company (2021-2026) Table 10. Global Drugs of Abuse Analysis Controls Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs of Abuse Analysis Controls Key Company Manufacturing Base & Headquarters Table 12. Global Drugs of Abuse Analysis Controls Company, Product Type & Application Table 13. Global Drugs of Abuse Analysis Controls Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs of Abuse Analysis Controls by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Liquid Table 18. Significant Companies of Lyophilized Table 19. Significant Companies of Others Table 20. Global Drugs of Abuse Analysis Controls Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Drugs of Abuse Analysis Controls Sales Volume by Type (2021-2026) & (k units) Table 22. Global Drugs of Abuse Analysis Controls Sales Volume by Type (2027-2032) & (k units) Table 23. Global Drugs of Abuse Analysis Controls Sales Volume Share by Type (2021-2026) Table 24. Global Drugs of Abuse Analysis Controls Sales Volume Share by Type (2027-2032) Table 25. Global Drugs of Abuse Analysis Controls Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs of Abuse Analysis Controls Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Drugs of Abuse Analysis Controls Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Drugs of Abuse Analysis Controls Sales Value Share by Type (2021-2026) Table 29. Global Drugs of Abuse Analysis Controls Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinical Table 31. Significant Companies of Diagnostic Laboratories Table 32. Significant Companies of Hospital Table 33. Significant Companies of Others Table 34. Global Drugs of Abuse Analysis Controls Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Drugs of Abuse Analysis Controls Sales Volume by Application (2021-2026) & (k units) Table 36. Global Drugs of Abuse Analysis Controls Sales Volume by Application (2027-2032) & (k units) Table 37. Global Drugs of Abuse Analysis Controls Sales Volume Share by Application (2021-2026) Table 38. Global Drugs of Abuse Analysis Controls Sales Volume Share by Application (2027-2032) Table 39. Global Drugs of Abuse Analysis Controls Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Drugs of Abuse Analysis Controls Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Drugs of Abuse Analysis Controls Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Drugs of Abuse Analysis Controls Sales Value Share by Application (2021-2026) Table 43. Global Drugs of Abuse Analysis Controls Sales Value Share by Application (2027-2032) Table 44. Global Drugs of Abuse Analysis Controls Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Drugs of Abuse Analysis Controls Sales by Region (2021-2026) & (k units) Table 46. Global Drugs of Abuse Analysis Controls Sales Market Share by Region (2021-2026) Table 47. Global Drugs of Abuse Analysis Controls Sales by Region (2027-2032) & (k units) Table 48. Global Drugs of Abuse Analysis Controls Sales Market Share by Region (2027-2032) Table 49. Global Drugs of Abuse Analysis Controls Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Drugs of Abuse Analysis Controls Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Drugs of Abuse Analysis Controls Sales Value Share by Region (2021-2026) Table 52. Global Drugs of Abuse Analysis Controls Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Drugs of Abuse Analysis Controls Sales Value Share by Region (2027-2032) Table 54. Global Drugs of Abuse Analysis Controls Market Average Price (USD/unit) by Region (2021-2026) Table 55. Global Drugs of Abuse Analysis Controls Market Average Price (USD/unit) by Region (2027-2032) Table 56. Global Drugs of Abuse Analysis Controls Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Drugs of Abuse Analysis Controls Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Drugs of Abuse Analysis Controls Sales by Country (2021-2026) & (k units) Table 59. Global Drugs of Abuse Analysis Controls Sales Market Share by Country (2021-2026) Table 60. Global Drugs of Abuse Analysis Controls Sales by Country (2027-2032) & (k units) Table 61. Global Drugs of Abuse Analysis Controls Sales Market Share by Country (2027-2032) Table 62. Global Drugs of Abuse Analysis Controls Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Drugs of Abuse Analysis Controls Sales Value Market Share by Country (2021-2026) Table 64. Global Drugs of Abuse Analysis Controls Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Drugs of Abuse Analysis Controls Sales Value Market Share by Country (2027-2032) Table 66. American Bio Medica Corp Company Information Table 67. American Bio Medica Corp Business Overview Table 68. American Bio Medica Corp Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. American Bio Medica Corp Drugs of Abuse Analysis Controls Product Portfolio Table 70. American Bio Medica Corp Recent Development Table 71. Bio-Rad Laboratories Company Information Table 72. Bio-Rad Laboratories Business Overview Table 73. Bio-Rad Laboratories Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Bio-Rad Laboratories Drugs of Abuse Analysis Controls Product Portfolio Table 75. Bio-Rad Laboratories Recent Development Table 76. BTNX Company Information Table 77. BTNX Business Overview Table 78. BTNX Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. BTNX Drugs of Abuse Analysis Controls Product Portfolio Table 80. BTNX Recent Development Table 81. Carolina Liquid Chemistries Company Information Table 82. Carolina Liquid Chemistries Business Overview Table 83. Carolina Liquid Chemistries Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Carolina Liquid Chemistries Drugs of Abuse Analysis Controls Product Portfolio Table 85. Carolina Liquid Chemistries Recent Development Table 86. Cerilliant Company Information Table 87. Cerilliant Business Overview Table 88. Cerilliant Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Cerilliant Drugs of Abuse Analysis Controls Product Portfolio Table 90. Cerilliant Recent Development Table 91. Clarity Diagnostics LLC Company Information Table 92. Clarity Diagnostics LLC Business Overview Table 93. Clarity Diagnostics LLC Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Clarity Diagnostics LLC Drugs of Abuse Analysis Controls Product Portfolio Table 95. Clarity Diagnostics LLC Recent Development Table 96. Diatron Company Information Table 97. Diatron Business Overview Table 98. Diatron Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Diatron Drugs of Abuse Analysis Controls Product Portfolio Table 100. Diatron Recent Development Table 101. JAS Diagnostics Company Information Table 102. JAS Diagnostics Business Overview Table 103. JAS Diagnostics Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. JAS Diagnostics Drugs of Abuse Analysis Controls Product Portfolio Table 105. JAS Diagnostics Recent Development Table 106. Kova International Company Information Table 107. Kova International Business Overview Table 108. Kova International Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Kova International Drugs of Abuse Analysis Controls Product Portfolio Table 110. Kova International Recent Development Table 111. Lin-Zhi International Inc Company Information Table 112. Lin-Zhi International Inc Business Overview Table 113. Lin-Zhi International Inc Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Lin-Zhi International Inc Drugs of Abuse Analysis Controls Product Portfolio Table 115. Lin-Zhi International Inc Recent Development Table 116. MedTest DX Company Information Table 117. MedTest DX Business Overview Table 118. MedTest DX Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. MedTest DX Drugs of Abuse Analysis Controls Product Portfolio Table 120. MedTest DX Recent Development Table 121. Microgenics Company Information Table 122. Microgenics Business Overview Table 123. Microgenics Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Microgenics Drugs of Abuse Analysis Controls Product Portfolio Table 125. Microgenics Recent Development Table 126. Ortho Clinical Diagnostics Company Information Table 127. Ortho Clinical Diagnostics Business Overview Table 128. Ortho Clinical Diagnostics Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Ortho Clinical Diagnostics Drugs of Abuse Analysis Controls Product Portfolio Table 130. Ortho Clinical Diagnostics Recent Development Table 131. Quasar Instruments Company Information Table 132. Quasar Instruments Business Overview Table 133. Quasar Instruments Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Quasar Instruments Drugs of Abuse Analysis Controls Product Portfolio Table 135. Quasar Instruments Recent Development Table 136. QuidelOrtho Corporation Company Information Table 137. QuidelOrtho Corporation Business Overview Table 138. QuidelOrtho Corporation Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. QuidelOrtho Corporation Drugs of Abuse Analysis Controls Product Portfolio Table 140. QuidelOrtho Corporation Recent Development Table 141. Beckman Coulter Company Information Table 142. Beckman Coulter Business Overview Table 143. Beckman Coulter Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Beckman Coulter Drugs of Abuse Analysis Controls Product Portfolio Table 145. Beckman Coulter Recent Development Table 146. Horiba Company Information Table 147. Horiba Business Overview Table 148. Horiba Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Horiba Drugs of Abuse Analysis Controls Product Portfolio Table 150. Horiba Recent Development Table 151. Thermo Fisher Scientific Company Information Table 152. Thermo Fisher Scientific Business Overview Table 153. Thermo Fisher Scientific Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. Thermo Fisher Scientific Drugs of Abuse Analysis Controls Product Portfolio Table 155. Thermo Fisher Scientific Recent Development Table 156. Siemens Company Information Table 157. Siemens Business Overview Table 158. Siemens Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. Siemens Drugs of Abuse Analysis Controls Product Portfolio Table 160. Siemens Recent Development Table 161. Abbott Company Information Table 162. Abbott Business Overview Table 163. Abbott Drugs of Abuse Analysis Controls Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Abbott Drugs of Abuse Analysis Controls Product Portfolio Table 165. Abbott Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Drugs of Abuse Analysis Controls Distributors List Table 169. Drugs of Abuse Analysis Controls Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Drugs of Abuse Analysis Controls Product Image Figure 2. Global Drugs of Abuse Analysis Controls Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs of Abuse Analysis Controls Sales (2021-2032) & (k units) Figure 5. Global Drugs of Abuse Analysis Controls Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Drugs of Abuse Analysis Controls Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Liquid Image Figure 10. Lyophilized Image Figure 11. Others Image Figure 12. Global Drugs of Abuse Analysis Controls Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Drugs of Abuse Analysis Controls Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs of Abuse Analysis Controls Sales Volume Share by Type (2021-2032) Figure 15. Global Drugs of Abuse Analysis Controls Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs of Abuse Analysis Controls Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs of Abuse Analysis Controls Sales Value Share by Type (2021-2032) Figure 18. Clinical Image Figure 19. Diagnostic Laboratories Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Drugs of Abuse Analysis Controls Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Drugs of Abuse Analysis Controls Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs of Abuse Analysis Controls Sales Volume Share by Application (2021-2032) Figure 25. Global Drugs of Abuse Analysis Controls Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Drugs of Abuse Analysis Controls Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Drugs of Abuse Analysis Controls Sales Value Share by Application (2021-2032) Figure 28. Global Drugs of Abuse Analysis Controls Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Drugs of Abuse Analysis Controls Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Drugs of Abuse Analysis Controls Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Drugs of Abuse Analysis Controls Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 33. North America Drugs of Abuse Analysis Controls Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Drugs of Abuse Analysis Controls Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Drugs of Abuse Analysis Controls Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 39. South America Drugs of Abuse Analysis Controls Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Drugs of Abuse Analysis Controls Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Drugs of Abuse Analysis Controls Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Drugs of Abuse Analysis Controls Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Drugs of Abuse Analysis Controls Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Lyophilized
  • Others
Applications
  • Clinical
  • Diagnostic Laboratories
  • Hospital
  • Others
Companies covered
  • American Bio Medica Corp
  • Bio-Rad Laboratories
  • BTNX
  • Carolina Liquid Chemistries
  • Cerilliant
  • Clarity Diagnostics LLC
  • Diatron
  • JAS Diagnostics
  • Kova International
  • Lin-Zhi International Inc
  • MedTest DX
  • Microgenics
  • Ortho Clinical Diagnostics
  • Quasar Instruments
  • QuidelOrtho Corporation
  • Beckman Coulter
  • Horiba
  • Thermo Fisher Scientific
  • Siemens
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  4. 1.2.2 Global Drugs of Abuse Analysis Controls Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs of Abuse Analysis Controls Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs of Abuse Analysis Controls Market Dynamics
  1. 2.1 Drugs of Abuse Analysis Controls Industry Trends
  2. 2.2 Drugs of Abuse Analysis Controls Industry Drivers
  3. 2.3 Drugs of Abuse Analysis Controls Industry Opportunities and Challenges
  4. 2.4 Drugs of Abuse Analysis Controls Industry Restraints
3 Drugs of Abuse Analysis Controls Market by Company
  1. 3.1 Global Drugs of Abuse Analysis Controls Company Revenue Ranking in 2025
  2. 3.2 Global Drugs of Abuse Analysis Controls Revenue by Company (2021-2026)
  3. 3.3 Global Drugs of Abuse Analysis Controls Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs of Abuse Analysis Controls Average Price by Company (2021-2026)
  5. 3.5 Global Drugs of Abuse Analysis Controls Company Ranking (2024-2026)
  6. 3.6 Global Drugs of Abuse Analysis Controls Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs of Abuse Analysis Controls Company Product Type and Application
  8. 3.8 Global Drugs of Abuse Analysis Controls Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs of Abuse Analysis Controls Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs of Abuse Analysis Controls Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs of Abuse Analysis Controls Market by Type
  1. 4.1 Drugs of Abuse Analysis Controls Type Introduction
  2. 4.1.1 Liquid
  3. 4.1.2 Lyophilized
  4. 4.1.3 Others
  5. 4.2 Global Drugs of Abuse Analysis Controls Sales Volume by Type
  6. 4.2.1 Global Drugs of Abuse Analysis Controls Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs of Abuse Analysis Controls Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Drugs of Abuse Analysis Controls Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Drugs of Abuse Analysis Controls Sales Value by Type
  10. 4.3.1 Global Drugs of Abuse Analysis Controls Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs of Abuse Analysis Controls Sales Value by Type (2021-2032)
  12. 4.3.3 Global Drugs of Abuse Analysis Controls Sales Value Share by Type (2021-2032)
5 Drugs of Abuse Analysis Controls Market by Application
  1. 5.1 Drugs of Abuse Analysis Controls Application Introduction
  2. 5.1.1 Clinical
  3. 5.1.2 Diagnostic Laboratories
  4. 5.1.3 Hospital
  5. 5.1.4 Others
  6. 5.2 Global Drugs of Abuse Analysis Controls Sales Volume by Application
  7. 5.2.1 Global Drugs of Abuse Analysis Controls Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drugs of Abuse Analysis Controls Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Drugs of Abuse Analysis Controls Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Drugs of Abuse Analysis Controls Sales Value by Application
  11. 5.3.1 Global Drugs of Abuse Analysis Controls Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Drugs of Abuse Analysis Controls Sales Value by Application (2021-2032)
  13. 5.3.3 Global Drugs of Abuse Analysis Controls Sales Value Share by Application (2021-2032)
6 Drugs of Abuse Analysis Controls Regional Sales and Value Analysis
  1. 6.1 Global Drugs of Abuse Analysis Controls Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs of Abuse Analysis Controls Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs of Abuse Analysis Controls Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs of Abuse Analysis Controls Sales by Region (2027-2032)
  5. 6.3 Global Drugs of Abuse Analysis Controls Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs of Abuse Analysis Controls Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs of Abuse Analysis Controls Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs of Abuse Analysis Controls Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs of Abuse Analysis Controls Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  12. 6.6.2 North America Drugs of Abuse Analysis Controls Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs of Abuse Analysis Controls Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs of Abuse Analysis Controls Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  21. 6.9.2 South America Drugs of Abuse Analysis Controls Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs of Abuse Analysis Controls Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs of Abuse Analysis Controls Sales Value Share by Country, 2025 VS 2032
7 Drugs of Abuse Analysis Controls Country-level Sales and Value Analysis
  1. 7.1 Global Drugs of Abuse Analysis Controls Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs of Abuse Analysis Controls Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs of Abuse Analysis Controls Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs of Abuse Analysis Controls Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs of Abuse Analysis Controls Sales by Country (2027-2032)
  6. 7.4 Global Drugs of Abuse Analysis Controls Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs of Abuse Analysis Controls Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs of Abuse Analysis Controls Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs of Abuse Analysis Controls Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs of Abuse Analysis Controls Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs of Abuse Analysis Controls Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 American Bio Medica Corp
  2. 8.1.1 American Bio Medica Corp Company Information
  3. 8.1.2 American Bio Medica Corp Business Overview
  4. 8.1.3 American Bio Medica Corp Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 American Bio Medica Corp Drugs of Abuse Analysis Controls Product Portfolio
  6. 8.1.5 American Bio Medica Corp Recent Developments
  7. 8.2 Bio-Rad Laboratories
  8. 8.2.1 Bio-Rad Laboratories Company Information
  9. 8.2.2 Bio-Rad Laboratories Business Overview
  10. 8.2.3 Bio-Rad Laboratories Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Rad Laboratories Drugs of Abuse Analysis Controls Product Portfolio
  12. 8.2.5 Bio-Rad Laboratories Recent Developments
  13. 8.3 BTNX
  14. 8.3.1 BTNX Company Information
  15. 8.3.2 BTNX Business Overview
  16. 8.3.3 BTNX Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BTNX Drugs of Abuse Analysis Controls Product Portfolio
  18. 8.3.5 BTNX Recent Developments
  19. 8.4 Carolina Liquid Chemistries
  20. 8.4.1 Carolina Liquid Chemistries Company Information
  21. 8.4.2 Carolina Liquid Chemistries Business Overview
  22. 8.4.3 Carolina Liquid Chemistries Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Carolina Liquid Chemistries Drugs of Abuse Analysis Controls Product Portfolio
  24. 8.4.5 Carolina Liquid Chemistries Recent Developments
  25. 8.5 Cerilliant
  26. 8.5.1 Cerilliant Company Information
  27. 8.5.2 Cerilliant Business Overview
  28. 8.5.3 Cerilliant Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cerilliant Drugs of Abuse Analysis Controls Product Portfolio
  30. 8.5.5 Cerilliant Recent Developments
  31. 8.6 Clarity Diagnostics LLC
  32. 8.6.1 Clarity Diagnostics LLC Company Information
  33. 8.6.2 Clarity Diagnostics LLC Business Overview
  34. 8.6.3 Clarity Diagnostics LLC Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Clarity Diagnostics LLC Drugs of Abuse Analysis Controls Product Portfolio
  36. 8.6.5 Clarity Diagnostics LLC Recent Developments
  37. 8.7 Diatron
  38. 8.7.1 Diatron Company Information
  39. 8.7.2 Diatron Business Overview
  40. 8.7.3 Diatron Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Diatron Drugs of Abuse Analysis Controls Product Portfolio
  42. 8.7.5 Diatron Recent Developments
  43. 8.8 JAS Diagnostics
  44. 8.8.1 JAS Diagnostics Company Information
  45. 8.8.2 JAS Diagnostics Business Overview
  46. 8.8.3 JAS Diagnostics Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 JAS Diagnostics Drugs of Abuse Analysis Controls Product Portfolio
  48. 8.8.5 JAS Diagnostics Recent Developments
  49. 8.9 Kova International
  50. 8.9.1 Kova International Company Information
  51. 8.9.2 Kova International Business Overview
  52. 8.9.3 Kova International Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kova International Drugs of Abuse Analysis Controls Product Portfolio
  54. 8.9.5 Kova International Recent Developments
  55. 8.10 Lin-Zhi International Inc
  56. 8.10.1 Lin-Zhi International Inc Company Information
  57. 8.10.2 Lin-Zhi International Inc Business Overview
  58. 8.10.3 Lin-Zhi International Inc Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lin-Zhi International Inc Drugs of Abuse Analysis Controls Product Portfolio
  60. 8.10.5 Lin-Zhi International Inc Recent Developments
  61. 8.11 MedTest DX
  62. 8.11.1 MedTest DX Company Information
  63. 8.11.2 MedTest DX Business Overview
  64. 8.11.3 MedTest DX Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 MedTest DX Drugs of Abuse Analysis Controls Product Portfolio
  66. 8.11.5 MedTest DX Recent Developments
  67. 8.12 Microgenics
  68. 8.12.1 Microgenics Company Information
  69. 8.12.2 Microgenics Business Overview
  70. 8.12.3 Microgenics Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Microgenics Drugs of Abuse Analysis Controls Product Portfolio
  72. 8.12.5 Microgenics Recent Developments
  73. 8.13 Ortho Clinical Diagnostics
  74. 8.13.1 Ortho Clinical Diagnostics Company Information
  75. 8.13.2 Ortho Clinical Diagnostics Business Overview
  76. 8.13.3 Ortho Clinical Diagnostics Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ortho Clinical Diagnostics Drugs of Abuse Analysis Controls Product Portfolio
  78. 8.13.5 Ortho Clinical Diagnostics Recent Developments
  79. 8.14 Quasar Instruments
  80. 8.14.1 Quasar Instruments Company Information
  81. 8.14.2 Quasar Instruments Business Overview
  82. 8.14.3 Quasar Instruments Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Quasar Instruments Drugs of Abuse Analysis Controls Product Portfolio
  84. 8.14.5 Quasar Instruments Recent Developments
  85. 8.15 QuidelOrtho Corporation
  86. 8.15.1 QuidelOrtho Corporation Company Information
  87. 8.15.2 QuidelOrtho Corporation Business Overview
  88. 8.15.3 QuidelOrtho Corporation Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 QuidelOrtho Corporation Drugs of Abuse Analysis Controls Product Portfolio
  90. 8.15.5 QuidelOrtho Corporation Recent Developments
  91. 8.16 Beckman Coulter
  92. 8.16.1 Beckman Coulter Company Information
  93. 8.16.2 Beckman Coulter Business Overview
  94. 8.16.3 Beckman Coulter Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Beckman Coulter Drugs of Abuse Analysis Controls Product Portfolio
  96. 8.16.5 Beckman Coulter Recent Developments
  97. 8.17 Horiba
  98. 8.17.1 Horiba Company Information
  99. 8.17.2 Horiba Business Overview
  100. 8.17.3 Horiba Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Horiba Drugs of Abuse Analysis Controls Product Portfolio
  102. 8.17.5 Horiba Recent Developments
  103. 8.18 Thermo Fisher Scientific
  104. 8.18.1 Thermo Fisher Scientific Company Information
  105. 8.18.2 Thermo Fisher Scientific Business Overview
  106. 8.18.3 Thermo Fisher Scientific Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Thermo Fisher Scientific Drugs of Abuse Analysis Controls Product Portfolio
  108. 8.18.5 Thermo Fisher Scientific Recent Developments
  109. 8.19 Siemens
  110. 8.19.1 Siemens Company Information
  111. 8.19.2 Siemens Business Overview
  112. 8.19.3 Siemens Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Siemens Drugs of Abuse Analysis Controls Product Portfolio
  114. 8.19.5 Siemens Recent Developments
  115. 8.20 Abbott
  116. 8.20.1 Abbott Company Information
  117. 8.20.2 Abbott Business Overview
  118. 8.20.3 Abbott Drugs of Abuse Analysis Controls Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Abbott Drugs of Abuse Analysis Controls Product Portfolio
  120. 8.20.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs of Abuse Analysis Controls Value Chain Analysis
  2. 9.1.1 Drugs of Abuse Analysis Controls Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs of Abuse Analysis Controls Sales Mode & Process
  6. 9.2 Drugs of Abuse Analysis Controls Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs of Abuse Analysis Controls Distributors
  9. 9.2.3 Drugs of Abuse Analysis Controls Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst